Shares of Destiny Pharma plc (LON:DEST – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 7.60 ($0.10) and last traded at GBX 8.65 ($0.11), with a volume of 401292 shares traded. The stock had previously closed at GBX 8.50 ($0.11).
Wall Street Analyst Weigh In
Separately, Shore Capital reissued a “house stock” rating on shares of Destiny Pharma in a research report on Wednesday, June 12th.
View Our Latest Analysis on DEST
Destiny Pharma Price Performance
Destiny Pharma Company Profile
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.
See Also
- Five stocks we like better than Destiny Pharma
- 10 Best Airline Stocks to Buy
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- The How And Why of Investing in Oil Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- EV Stocks and How to Profit from Them
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.